Hepatic Exosomes

Overview

Parent Cell: Akira Hepatic Stem Cells differentiated from UCT-WJ-MSCs | Hepatocyte-regulatory growth factors and miRNAs for liver repair and regeneration

Related: Exosomes Overview • Hepatic Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

The Akira Hepatic Exosome Matrix is derived from hepatic stem cells (HSCs) produced by a multi-stage directed differentiation protocol: definitive endoderm (Activin-A/Wnt3a) → hepatic specification (FGF-4/BMP-4) → hepatocyte maturation (Oncostatin-M/HGF/dexamethasone). The resulting hepatocyte-like cells express HNF4α, albumin (ALB), CYP3A4, and ASGR1 — key markers of mature hepatocyte identity — confirming lineage fidelity prior to exosome harvest.

miR-122 is the liver-specific miRNA expressed at high levels almost exclusively in hepatocytes, accounting for approximately 70% of total hepatic miRNA. Its presence in the Hepatic Exosome Matrix cargo is a direct confirmation of liver lineage identity and provides the unique hepatocyte-regulatory functions of this miRNA — including lipid metabolism regulation, viral hepatitis suppression, and hepatocyte differentiation maintenance — in exosome-delivered form.^[1]

Mechanism of Action

Hepatocyte Regeneration (HGF Pathway): HGF is the master hepatic regeneration factor, activating c-Met on hepatocytes to drive proliferation during liver regeneration — the same pathway activated during natural liver regeneration following hepatectomy, and characterized by HGF's core molecular structure and role in liver regeneration.^[2] EGF provides complementary mitogenic support. Together these growth factors drive hepatocyte re-entry into the cell cycle, critical in acute liver failure and the regenerative phase of chronic liver disease — an application area also being investigated directly with exosome-based drug-loading systems.^[3]

Hepatic Fibrosis Resolution: Hepatic stellate cell (HSC) activation to myofibroblasts is the central driver of liver fibrosis in chronic liver disease. HGF and TGF-β3 antagonize TGF-β1-mediated stellate cell activation — HGF specifically inhibits collagen I and IV synthesis in hepatic stellate cells via miR-29 induction.^[4] miR-let7 suppresses TGF-β pathway components in activated stellate cells. IL-6 from the hepatic secretome paradoxically provides hepatoprotective STAT3 signaling in hepatocytes while suppressing stellate cell fibrogenic activity. These combined anti-fibrotic mechanisms are relevant to NASH, alcoholic liver disease, and viral hepatitis-associated fibrosis — the subject of an ongoing clinical trial of MSC-derived exosomes in decompensated liver cirrhosis^[5] and a planned trial of exosome injection for chronic-to-acute liver failure.^[6]

Liver Inflammation & Immune Modulation: miR-146a suppresses Kupffer cell NF-κB activation via the same NF-κB-microRNA regulatory network that tunes macrophage inflammatory responses more broadly,^[7] reducing the hepatic macrophage-driven inflammatory cascade in drug-induced liver injury, viral hepatitis, and NASH. IL-10 from the secretome promotes Kupffer cell M2 polarization. miR-21 suppresses PDCD4 in hepatocytes, protecting against TNF-α-induced apoptosis. This hepatic anti-inflammatory program addresses the chronic necro-inflammation driving fibrosis progression.

Lipid Metabolism & NASH: miR-122 regulates hepatic lipid metabolism by modulating fatty acid synthesis (FASN) and cholesterol biosynthesis pathways — consistent with its broader recognized potential in liver disease diagnosis, prognosis, and therapy as both a miRNA mimic and antimir target.^[8] Loss of miR-122 in NASH is associated with progressive steatohepatitis and fibrosis. Exosome-delivered miR-122 restoration addresses this miRNA deficit in the NASH liver, potentially reducing steatosis and inflammatory lipotoxicity. HNF4α-associated cargo maintains hepatocyte metabolic identity and lipid handling function.^[9]

Key Molecular Cargo

Potential Applications

• Acute Liver Failure: HGF/EGF hepatocyte regeneration; miR-21 anti-apoptotic; Kupffer cell anti-inflammatory modulation.
• NASH / NAFLD Research: miR-122 lipid metabolism restoration; HGF/TGF-β3 anti-fibrotic activity.
• Liver Fibrosis & Cirrhosis: Stellate cell deactivation via HGF/TGF-β3/miR-let7; Kupffer cell modulation.
• Viral Hepatitis Research: Anti-inflammatory cargo reduces hepatic necro-inflammation and supports tissue repair in preclinical hepatitis models.
• Drug-Induced Liver Injury: miR-21/HGF anti-apoptotic cargo; Kupffer cell anti-inflammatory modulation.
• Alcoholic Liver Disease: Anti-inflammatory secretome addresses ethanol-driven Kupffer activation.
• Primary Biliary Cholangitis: Cholangiocyte support via EGF; anti-inflammatory macrophage modulation.
• Liver Transplant Research: Anti-inflammatory and hepatoprotective cargo relevant to ischemia-reperfusion injury and chronic rejection research.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

The evidence base for this preparation is preclinical and mechanistic rather than product-specific clinical trial data — hepatocyte exosomes are established mediators of liver repair and regeneration via sphingosine-1-phosphate signaling,^[10] hucMSC exosome-derived GPX1 has been shown necessary for recovery from hepatic oxidant injury,^[11] and WJ-MSC exosomes show dose-responsive anti-fibrotic efficacy in liver fibrosis models.^[12] See the Akira Hepatic Stem Cells guide for whole-cell trial data from the same lineage, including a 2024 meta-analysis across 15 RCTs in cirrhosis, acute liver failure, and NASH.